Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Accenture
Citi
Express Scripts
US Department of Justice

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 9,040,567

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,040,567
Title:BAX agonist, compositions, and methods related thereto
Abstract: The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
Inventor(s): Deng; Xingming (Lilburn, GA), Zhou; Jia (League City, TX), Ding; Chunyong (Shanghai, CN)
Assignee: Emory University (Atlanta, GA) Board of Regents of the University of Texas System (Austin, TX)
Application Number:14/239,177
Patent Claims:see list of patent claims

Details for Patent 9,040,567

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Emory University (Atlanta, GA) Board of Regents of the University of Texas System (Austin, TX) 2036-04-30 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Emory University (Atlanta, GA) Board of Regents of the University of Texas System (Austin, TX) 2036-04-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Emory University (Atlanta, GA) Board of Regents of the University of Texas System (Austin, TX) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Emory University (Atlanta, GA) Board of Regents of the University of Texas System (Austin, TX) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Citi
Cipla
McKinsey
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.